Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. hormone insulin
Show results for
Products
Services
Applications

Companies

News
Articles

Refine by
Date

  • Older

Hormone Insulin Articles & Analysis

13 news found

CD Formulation Empowers High-volume Manufacturing of Microspheres

CD Formulation Empowers High-volume Manufacturing of Microspheres

The types of microsphere products that CD Formulation can provide include polymer microspheres, parathyroid hormone microspheres, calcitonin microspheres, insulin microspheres, and more. ...

ByCD Formulation


CD Formulation Introduces Comprehensive Range of Microsphere and Microneedle Solutions for Pharma and Biotech Applications

CD Formulation Introduces Comprehensive Range of Microsphere and Microneedle Solutions for Pharma and Biotech Applications

Below are the main microsphere and microneedle solutions provided by CD Formulation: Microsphere and Microneedle Patch Preparation ServicesCD Formulation's research team offers a wide range of microneedle preparations with smooth tip surfaces and clear tip details, for melatonin microneedle patch, parathyroid hormone microneedle patch, exenatide microneedle patch, ...

ByCD Formulation


Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases

Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases

However, despite the remarkable impact of FDA-approved biologics based on secreted proteins such as insulin, human growth hormone, and erythropoietin, this class of biologics has remained largely understudied and underutilized by biopharma due to low abundance, higher structural complexity, and the massive search space to map secreted proteins to ...

ByJuvena Therapeutics, inc.


Analysis supporting treatment with Diamyd published in peer-reviewed scientific journal

Analysis supporting treatment with Diamyd published in peer-reviewed scientific journal

The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase IIb trial DIAGNODE-2, where the diabetes vaccine was administered directly into a lymph node ...

ByDiamyd Medical AB


Immunological analysis of prevention trial with Diamyd published in peer-reviewed scientific journal

Immunological analysis of prevention trial with Diamyd published in peer-reviewed scientific journal

The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase IIb trial DIAGNODE-2, where the diabetes vaccine was administered directly into a lymph node ...

ByDiamyd Medical AB


All patients in DiagnodE-B have received an additional (booster) injection of Diamyd

All patients in DiagnodE-B have received an additional (booster) injection of Diamyd

“In our first trial with intralymphatically administered Diamyd, DIAGNODE-1, all three individuals who received a fourth injection preserved their own insulin production over at least one additional year, which is ...

ByDiamyd Medical AB


Updated results from clinical trial with Diamyd presented today at diabetes conference

Updated results from clinical trial with Diamyd presented today at diabetes conference

Median glucagon-stimulated C-peptide levels, an alternative measure of endogenous insulin production, were unchanged at 12 months compared to baseline in the HLA DR3-DQ2 positive patients, indicating complete preservation of insulin producing capacity. ...

ByDiamyd Medical AB


Five-month results from Diamyd trial in LADA published in peer-reviewed scientific journal

Five-month results from Diamyd trial in LADA published in peer-reviewed scientific journal

LADA is characterized by an ongoing autoimmune destruction of the insulin-producing beta cells, a process similar to that of type 1 diabetes, but slower. Although research categorizes LADA as autoimmune diabetes, the disease is still in most cases treated according to the guidelines for type 2 diabetes. LADA patients are usually not insulin dependent at ...

ByDiamyd Medical AB


Promising topline results for intralymphatic Diamyd in patients with LADA

Promising topline results for intralymphatic Diamyd in patients with LADA

The clinical course appears positive with all 14 individuals remaining insulin-independent after 12 months of follow-up. The endogenous insulin production, measured as mixed-meal stimulated C-peptide, declined on average only 10% over 12 months. ...

ByDiamyd Medical AB


Diamyd Medical joins international consortium in Type 1 Diabetes

Diamyd Medical joins international consortium in Type 1 Diabetes

Of particular interest for Diamyd Medical will be the advancement of C-peptide preservation (a biomarker for the body’s own insulin production) as a primary endpoint for regulatory approval. Another focus for Diamyd Medical will include developing Continuous Glucose Monitoring (CGM) as an endpoint fit for regulatory approval. ...

ByDiamyd Medical AB


First patient enrolled in Diamyd Medical`s Phase III trial Diagnode-3

First patient enrolled in Diamyd Medical`s Phase III trial Diagnode-3

” “Preserving some own insulin secretion is the best way to mitigate type 1 diabetes, prevent complications and provide a good quality of life," says Johnny Ludvigsson, Professor at Linköping University and Coordinating Iinvestigator for DIAGNODE-3. ...

ByDiamyd Medical AB


New Study Explains How BPA May Cause Diabetes and Weight Gain

New Study Explains How BPA May Cause Diabetes and Weight Gain

Past studies have linked the chemical to obesity and diabetes (as well as a greater risk of cancer, heart disease, and behavioral problems in young children), but now findings published in the journal PLoS ONE show how even miniscule amounts of BPA can trick the body into making more fat. BPA, masquerading as the hormone and insulin regulator estrogen, fools ...

ByEMSL Analytical, Inc.


NGOs call for EPA pesticide testing to be updated

NGOs call for EPA pesticide testing to be updated

Colborn argues that EPA's limited approach will not detect chemicals that can alter development and function of the pancreas, and its hormone, insulin, which could lead to diabetes and obesity. It also will not detect chemicals that alter how the brain is constructed and programmed that can undermine intelligence and behaviour. ...

ByHealth and Environment Alliance (HEAL)

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT